Novo Nordisk's sales growth went from 14 percent to zero – more uncertainty ahead

Following two quarters of very different sales growth, Novo Nordisk Chief Financial Officer Karsten Munk Knudsen warns of ongoing volatility due to the Covid-19 pandemic. More side effects are expected, but the worst may well be over, according to analyst.

Karsten Munk Knudsen, CFO, Novo Nordisk. Photo: Novo Nordisk / PR

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try MedWatch for 14 days.

Get a trial subscription here.

Do you want a trial subscription with multiple users for yourself and your colleagues?

Read more about your options and find the contact information to our sales team here.

Related articles